HONG KONG and FLORHAM PARK, N.J., April 22, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (HCM) (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that it has completed enrollment of the ...
HUTCHMED (China) Limited has completed patient enrollment for the registration phase of its Phase II trial assessing savolitinib in gastric cancer patients with MET amplification. This multi-center, ...
Savolitinib is an oral, potent, and highly selective MET tyrosine kinase inhibitor (“TKI”) being jointly developed by AstraZeneca and HUTCHMED and commercialized by AstraZeneca. MET is a tyrosine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results